A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis.
He-Xiang ZongSheng-Qian XuJian-Xiong WangYi-Ran ChuKe-Ming ChenCong WangWan-Qiu TongXi-le WangPublished in: Drug design, development and therapy (2022)
ASDAScrp improved slightly within 6 months after treatment with imrecoxib, and TNFi combined with imrecoxib significantly improved multiple effect indexes in axSpA patients. The efficacy of imrecoxib and celecoxib in the treatment of axSpA is equivalent. Also, they have the same efficacy after being combined with TNFi.